Evidence mapPaperPMID 39951058Full record

Trial reportDiabetologia2025

Differential associations of somatic and cognitive-affective symptoms of depression with inflammation and insulin resistance: cross-sectional and longitudinal results from the Emotional Distress Sub-Study of the GRADE study.

Dominic Ehrmann, Heidi Krause-Steinrauf, Diane Uschner, Hui Wen, Claire J Hoogendoorn, Gladys Crespo-Ramos, Caroline Presley, Valerie L Arends, Robert M Cohen, W Timothy Garvey and 5 more

Erratum issued Registry-linked trialAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Diabetologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It reports registered trial NCT01794143. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01794143 phase3completed

Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study

Ran2013Enrolled7,850Registered outcomes4Posted comparisons0ConditionsComparative Effectiveness of Glycemia-lowering Medications, Type 2 DiabetesArmsDPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide), Insulin (glargine), Sulfonylurea (glimepiride)
Open the trial in the graph
3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Dominic EhrmannResearch Institute Diabetes Academy Mergentheim (FIDAM), Bad Mergentheim, Germany. ehrmann@fidam.de.ORCID http://orcid.org/0000-0002-5794-5596
Heidi Krause-SteinraufThe Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Rockville, MD, USA.ORCID http://orcid.org/0000-0001-6894-4110
Diane UschnerThe Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Rockville, MD, USA.ORCID http://orcid.org/0000-0002-7858-796X
Hui WenThe Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Rockville, MD, USA.ORCID http://orcid.org/0000-0002-0597-7596
Claire J HoogendoornFerkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, USA.ORCID http://orcid.org/0000-0003-4526-1952
Gladys Crespo-RamosDepartment of Medicine (Endocrinology), Albert Einstein College of Medicine, Bronx, NY, USA.ORCID http://orcid.org/0000-0001-8781-1858
Caroline PresleyDepartment of Medicine (General Internal and Preventive Medicine), University of Alabama at Birmingham, Birmingham, AL, USA.ORCID http://orcid.org/0000-0001-6492-9941
Valerie L ArendsAdvanced Research and Diagnostic Laboratory, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Robert M CohenDivision of Endocrinology, Diabetes & Metabolism, Department of Medicine, University of Cincinnati College of Medicine & Endocrine Section, Cincinnati VA Medical Center, Cincinnati, OH, USA.
W Timothy GarveyUniversity of Alabama at Birmingham, Birmingham, AL, USA.
Thomas MartensInternational Diabetes Center, HealthPartners Institute, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0002-9858-2138
Holly J WillisInternational Diabetes Center, HealthPartners Institute, Minneapolis, MN, USA.ORCID http://orcid.org/0000-0002-2404-5751
Andrea CherringtonDepartment of Medicine (General Internal and Preventive Medicine), University of Alabama at Birmingham, Birmingham, AL, USA.
Jeffrey S GonzalezFerkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, USA.
GRADE Research Group

Funding

Continuation of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) StudyU01DK098246 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI Heidi Krause-Steinrauf, JOHN M LACHIN · 2021 to 2022
$21.0M
Washington University Institute of Clinical and Translational SciencesUL1TR002345 · WASHINGTON UNIVERSITY · 2025 to 2025
$9.3M
Clinical and Translational Science Collaborative of Northern Ohio, Catalyzing Linkages for Everyone's Health (CLE Health)UM1TR004528 · CASE WESTERN RESERVE UNIVERSITY · 2025 to 2025
$7.9M
NCATS NIH HHS UL1 TR002345NCATS NIH HHS UM1 TR004528NIDDK NIH HHS R01 DK104845NIDDK NIH HHS U01 DK098246NIDDK NIH HHS U01DK098246NIDDK NIH HHS U34 DK088043NIDDK NIH HHS U34-DK-088043
6 · The paper itself

Abstract

aims/hypothesisInsulin resistance and inflammation are components of a biological framework that is hypothesised to be shared by type 2 diabetes and depression. However, depressive symptoms include a large heterogeneity of somatic and cognitive-affective symptoms, and this may obscure the associations within this biological framework. Cross-sectional and longitudinal data were used to disentangle the contributions of insulin resistance and inflammation to somatic and cognitive-affective symptoms of depression.

methodsThis secondary analysis used data from the Emotional Distress Sub-Study of the GRADE trial. Insulin resistance and inflammation were assessed using the HOMA-IR estimation and high-sensitivity C-reactive protein (hsCRP) levels, respectively, at baseline and at the study visits at year 1 and year 3 (HOMA-IR) and every 6 months (hsCRP) for up to 3 years of follow-up. Depressive symptoms were assessed at baseline using the Patient Health Questionnaire (PHQ-8), and a total score as well as symptom cluster scores for cognitive-affective and somatic symptoms were calculated. For the cross-sectional analyses, linear regression analyses were performed, with inflammation and insulin resistance at baseline as dependent variables. For the longitudinal analyses, linear mixed-effect regression analyses were performed, with inflammation and insulin resistance at the various time points as dependent variables. In all analyses, depressive symptoms (total score and symptom cluster scores) were the independent variables, controlled for important demographic, anthropometric and metabolic confounders. For the analysis of insulin resistance (HOMA-IR), data from 1321 participants were analysed. For the analysis of inflammation (hsCRP), data from 1739 participants were analysed.

resultsIn cross-sectional analysis and after adjustment for potential confounders, a one-unit increase in PHQ-8 total score was significantly associated with a 0.8% increase in HOMA-IR (p=0.007), but not with hsCRP (0.6% increase, p=0.283). The somatic symptom score was associated with a 5.8% increase in HOMA-IR (p=0.004). Single-item analyses of depressive symptoms showed that fatigue (3.6% increase, p=0.002) and increased/decreased appetite (3.5% increase, p=0.009) were significantly associated with HOMA-IR cross-sectionally. The cognitive-affective symptom score was not significantly associated with HOMA-IR at baseline. In longitudinal analyses, a one-unit increase in PHQ-8 total score was significantly associated with a 0.8% increase in hsCRP over time (p=0.014), but not with HOMA-IR over time (0.1% decrease, p=0.564). Again, only the somatic symptom cluster was significantly associated with hsCRP over time (5.2% increase, p=0.017), while the cognitive-affective symptom score was not. CONCLUSION/

interpretationThe results highlight the associations of depressive symptoms with markers of inflammation and insulin resistance, both cross-sectionally and longitudinally, in individuals with type 2 diabetes. In particular, somatic symptoms of depression appear to be the driver of these associations, even after controlling for concomitant conditions, with a potential role for fatigue and issues with appetite.

trial registrationClinicalTrials.gov NCT01794143.

Indexed as

DepressionInflammationInsulin ResistanceAdultAgedCognitionC-Reactive ProteinCross-Sectional StudiesDiabetes Mellitus, Type 2FemaleHumansLongitudinal StudiesMaleMiddle AgedPsychological DistressC-Reactive ProteinDepressionInflammationInsulin resistanceSomatic symptomsType 2 diabetes

Identifiers

PMID39951058
PMCPMC12176517

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.